These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24862365)

  • 1. The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.
    Ponzoni L; Braida D; Pucci L; Andrea D; Fasoli F; Manfredi I; Papke RL; Stokes C; Cannazza G; Clementi F; Gotti C; Sala M
    Psychopharmacology (Berl); 2014 Dec; 231(24):4681-93. PubMed ID: 24862365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.
    Braida D; Ponzoni L; Martucci R; Sparatore F; Gotti C; Sala M
    Psychopharmacology (Berl); 2014 May; 231(9):1975-85. PubMed ID: 24311357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
    Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
    Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural and pharmacological profiles of zebrafish administrated pyrrolidinyl benzodioxanes and prolinol aryl ethers with high affinity for heteromeric nicotinic acetylcholine receptors.
    Braida D; Ponzoni L; Moretti M; Viani P; Pallavicini M; Bolchi C; Appiani R; Bavo F; Gotti C; Sala M
    Psychopharmacology (Berl); 2020 Aug; 237(8):2317-2326. PubMed ID: 32382782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
    Cunningham CS; McMahon LR
    Eur J Pharmacol; 2011 Mar; 654(1):47-52. PubMed ID: 21172344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.
    Riganti L; Matteoni C; Di Angelantonio S; Nistri A; Gaimarri A; Sparatore F; Canu-Boido C; Clementi F; Gotti C
    Br J Pharmacol; 2005 Dec; 146(8):1096-109. PubMed ID: 16273122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
    Spiller K; Xi ZX; Li X; Ashby CR; Callahan PM; Tehim A; Gardner EL
    Neuropharmacology; 2009 Jul; 57(1):60-6. PubMed ID: 19393252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.
    Biala G; Staniak N; Budzynska B
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Apr; 381(4):361-70. PubMed ID: 20217050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.
    Cunningham CS; Javors MA; McMahon LR
    J Pharmacol Exp Ther; 2012 Jun; 341(3):840-9. PubMed ID: 22438471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.
    Peng C; Stokes C; Mineur YS; Picciotto MR; Tian C; Eibl C; Tomassoli I; Guendisch D; Papke RL
    J Pharmacol Exp Ther; 2013 Nov; 347(2):424-37. PubMed ID: 23959137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
    Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
    J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
    Stokes C; Papke RL
    Neuropharmacology; 2012 Sep; 63(4):538-46. PubMed ID: 22580377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
    Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
    Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model.
    Świątkowski W; Budzyńska B; Maciąg M; Świątkowska A; Tylżanowski P; Rahnama-Hezavah M; Stachurski P; Chałas R
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
    Ortiz NC; O'Neill HC; Marks MJ; Grady SR
    Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
    Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
    Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.
    Cunningham CS; McMahon LR
    Psychopharmacology (Berl); 2013 Jul; 228(2):321-33. PubMed ID: 23494230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic receptor antagonists as treatments for nicotine abuse.
    Crooks PA; Bardo MT; Dwoskin LP
    Adv Pharmacol; 2014; 69():513-51. PubMed ID: 24484986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
    Mihalak KB; Carroll FI; Luetje CW
    Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.